SCHEMBL4233146

SCHEMBL4233146

O=c1c2ccccc2nc(-c2cccs2)n1N(Cc1ccc(C(F)(F)F)cc1)Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.52
HPGD P15428 7/20 0.52
ALDH1A1 P00352 6/20 0.52
POLB P06746 1/20 0.52
SMN1; SMN2 Q16637 4/20 0.48
NPSR1 Q6W5P4 2/20 0.48
LMNA P02545 6/20 0.47
HTT P42858 3/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
PLA2G1B P04054 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ATG4B Q9Y4P1 1/20 0.46
MAPK1 P28482 1/20 0.45
MAPT P10636 4/20 0.45
CXCR3 P49682 1/20 0.41
GAA P10253 2/20 0.41
RXFP1 Q9HBX9 2/20 0.41
PKM P14618 1/20 0.41
GBA1 P04062 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4237226 0.79 KDM4E (0.67) KDM4EHPGDALDH1A1POLBSMN1; SMN2
SCHEMBL5773420 0.71 CASR (0.68) KDM4EHPGDALDH1A1POLBSMN1; SMN2
SCHEMBL13700971 0.69 ALDH1A1 (0.70) KDM4EHPGDALDH1A1POLBSMN1; SMN2
SCHEMBL31276955 0.69 ALDH1A1 (0.70) KDM4EHPGDALDH1A1POLBSMN1; SMN2
SCHEMBL13700973 0.69 KDM4E (0.70) KDM4EHPGDALDH1A1POLBSMN1; SMN2
SCHEMBL4236261 0.66 KDM4E (0.69) KDM4EHPGDALDH1A1POLBSMN1; SMN2
SCHEMBL4238366 0.66 CASR (0.56) KDM4EALDH1A1SMN1; SMN2NPSR1LMNA
SCHEMBL4233257 0.65 ALDH1A1 (0.53) KDM4EHPGDALDH1A1POLBSMN1; SMN2
SCHEMBL4240220 0.64 ALDH1A1 (0.51) HPGDALDH1A1POLBSMN1; SMN2NPSR1
SCHEMBL4233248 0.63 ALDH1A1 (0.56) KDM4EHPGDALDH1A1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 KDM4E 3161/4885HPGD 1377/4885ALDH1A1 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.